A leading global health partnership working to reduce the burden of malaria. We discover, develop and deliver new antimalarial medicines.
Medicines for Malaria Venture (MMV)
Loading...
To accelerate #malaria elimination, next-gen antimalarials must be developed with simplicity in mind.
LAIs could provide lasting protection from a single intervention.
MMV & partners recently explored how this innovation can support high-burden settings: bit.ly/4wSkvCB
"The science has never looked so good or so promising."
The challenge is turning scientific progress into medicines that reach the people who need them.
Watch MMV's Emma Hannay on the importance of collaboration between @dndi.org, @gardp.bsky.social and MMV.
MMV’s Project of the Year 2025 is a powerful example of how we can go farther and faster by working together.
This week, we convened the partners behind Coartem® Baby, the first #malaria treatment specifically designed for newborns and young infants: bit.ly/4en79Xw
Another milestone in the treatment of vivax #malaria.
Thailand is the second country to approve paediatric tafenoquine, a single-dose treatment designed to help prevent relapse.
Co-developed by MMV and GSK, pTQ can help children recover without the threat of repeated relapse.
MMV’s 9th African call for proposals is now open!
We’re looking for projects that could help accelerate #malaria drug discovery, from assay development and AI-supported discovery to innovative biology and novel antimalarials.
Apply by 29 August: bit.ly/3Rt1h6j
#PressRelease @dndi.org, @gardp.bsky.social and MMV are joining forces to strengthen collaboration, maximize the impact of global health R&D, and accelerate the development of life-saving treatments.
Read the press release: bit.ly/4fo8xu0
As #malaria becomes more complex, we need simpler tools.
#Innovations like single-dose cures & long-acting injectables can accelerate elimination in complex settings.
Because the best innovations are the ones people actually use. That’s what makes them elimination accelerators.
What does it take to move new health technologies from pilot projects into routine care?
Last month in Thailand, MMV colleagues joined NMPs from across the Asia-Pacific to observe the implementation of tools for relapsing #malaria in real-world settings & exchange insights.
MMV delivered statements at #WHA79 this week, ensuring that #malaria is high on the global health agenda and strengthening the connection between elimination and broader health security.
Read the statements: bit.ly/49YdLZK
We join forces with @gardp.bsky.social & @mmv.org to accelerate drug development for patients in greatest need!
Emma Hannay, Chief Strategy Officer at MMV, explains why this collaboration is especially important in this changing global health ecosystem.
👉Press Release: dndi.org/press-releas...
